The European Union will impose fines on nine pharmaceutical companies with paid delayed transactions

Source: China Council for the promotion of drugs 2013-06-04 predicted that lundbeck was the hardest hit In recent months, regulators in the United States and the United Kingdom have been working to crack down on paid delayed transactions after the Supreme Court of the United States issued its opinion on paid delayed transactions in March Now it seems that EU regulators will join in EU antitrust regulators will impose fines on nine generic drug manufacturers who accept money to delay the launch of low-cost products Earlier this month, the European Commission will impose "iconic" fines on Denmark's lundbeck and eight other smaller pharmaceutical companies, Reuters quoted unnamed officials as saying Previous investigations began in 2009 The Commission reserves the right to impose fines of up to 10% of its global revenues on companies violating EU antitrust laws, which could amount to 2.4 million euros ($3.14 million) in the case of lundbeck, Reuters reported Merck and generics manufacturers Ranbaxy laboratories, UK generics, arrow, resolution chemicals, xellia pharmaceuticals, alpharma and Al industrier are also expected to be hit A spokesman for lundbeck told Reuters that although the company had not received notice of the fine, it would be hit hard if the European Commission imposed the fine While large pharmaceutical companies argue that paying generic manufacturers is to get them to give up the challenge, which is a legitimate patent protection and a strategy, European regulators estimate that consumers will pay as much as 20% more for their medicines as a result, Reuters said It's for this reason that opposition to such deals has been heating up: in April, the UK's office of fair trade accused GlaxoSmithKline of delaying products that have been approved by the European Commission for a year for a fee All of these actions came at a time when the U.S Supreme Court reviewed the court's ruling in the Federal Trade Commission v Actavis Inc., a lawsuit involving the patent settlement of Androgel between Actavis and Solvay pharmaceutical Original link: http://